PubMed Health⌕ Search

Biomedical subjects

H Rauschecker

Publications and source records attributed to H Rauschecker.

30 records · Page 2Linked to original sources
PubMed1988

[Achievements of tumor surgery in tumors of the breast].

Radical mastectomy (Rotter-Halsted) lowered the local and regional recurrence rate from 60% to 6%. Prospective randomized trials showed that there are no differences in overall survival or disease-free survival when a combination of simple mastectomy and lymph node dissection is used; the axillary recurrence rate was 1.8%. Adjuvant radiotherapy is superfluous. Conservative therapy should be reserved for stage I carcinomas in breast cancer.

Breast Neoplasms↗
PubMed1986

[Immunohistochemical studies of the determination of the hormone receptor status of breast cancer].

Immunohistochemical examinations of 89 breast cancer specimens were performed using two different monoclonal antibodies. One marked the nuclear estrogen-receptor (ER) protein (anti-ER, Abbott), whereas the other marked an ER-related cytoplasmic protein (ER-D5 Amersham). Comparison of the results of the biochemical assay with those of the immunohistochemical markers revealed the following correlations: 75% anti ER and 71% ER-D5. Clinical follow-up studies are necessary to specify the relevance of these new immunohistochemical techniques in the anti-hormonal therapeutic management of breast cancer patients.

Antibodies, Monoclonal↗
PubMed1985

[Tissue polypeptide antigen (TPA) and plasma TPA levels during the postoperative course in female primary breast carcinoma patients. 1st results of a long-term study].

TPA determinations can be used for monitoring advanced cancer patients. Increasing and decreasing TPA levels can be correlated to the further course of the disease. TPA levels should be determined in the postoperative follow-up of cancer patients with a higher risk of recurrence. Single point determinations for primary diagnosis is not recommended. Only the interpretation of long term evaluation studies in combination with clinical findings can be an advantage in managing cancer patients.

Adenocarcinoma, Scirrhous↗
PubMed1985

Determination of tissue polypeptide antigen (TPA) levels in different cancer types and controls.

The clinical significance of the radioimmunological determination of tissue polypeptide antigen (TPA) was studied in 1980 and 1981 in patients with different cancer types (cancer of the gastrointestinal tract, cancer of the genitourinary tract, cancer of the lung and other malignancies) as well as in patients with acute inflammatory diseases, other benign diseases and healthy controls. TPA levels were elevated in about 70% of patients with acute inflammatory diseases and in 50-80% of patients with malignancies having evidence of disease (ED). In all other groups, as healthy controls, benign diseases except inflammatory diseases and cancer patients who had no evidence of disease (NED) or partial remission (PR), TPA was above the normal range in 4-17%. Comparisons between cancer patients with ED and cancer patients with NED/PR, healthy controls and patients with benign diseases (without acute inflammatory diseases) have shown a significant difference (p less than 0.01). Data from a follow-up program from the years 1982 to 1984, including TPA determinations, are shown. TPA can be regarded as an additional 'marker' for proliferative processes. The test seems to be useful for monitoring cancer growth in advanced cancer patients who received chemo- or radiotherapy. Limitations result from the lack of tumor specificity of the marker TPA.

Adult↗
PubMed1983

[Plasma-prolactin concentrations in breast cancer at various stages, in mastopathy and other malignant tumors].

7% of 204 patients with metastatic breast cancer had hyperprolactinemia (greater than 1000 mIU/1 = 30.8 ng/ml) in the measurements of morning plasma prolactin basal levels. The incidence of hyperprolactinemia was significantly higher in patients with metastatic breast cancer than in 173 patients with non-metastatic breast cancer (p less than 0.001), in 151 patients with mastopathy (p = 0.01), in 63 patients with local (p = 0.001) and 56 patients with advanced solid tumors of different histology without prolactin stimulating medication (p = 0.001). After 5 measurements with a median interval of 2 months, elevated prolactin levels over 1000 mIU/l were found at least once in 35% of the patients with metastatic breast cancer. 93% of the women with hyperprolactinemic breast cancer were in progression at the time of the measurements, and none in remission; on the other hand, all patients with advanced breast cancer in remission had normal prolactin levels.

Adult↗
PubMed1983

Determination of TPA levels in breast cancer and controls.

The clinical significance of radioimmunological determination of Tissue Polypeptide Antigen (TPA) has been studied on patients with breast cancer (n = 376), on "normal subjects" (n = 92), on benign diseases of the breast as well as on patients with inflammatory diseases (n = 98). TPA levels were elevated (120 U/l or higher) in the group with inflammatory diseases in 68% and in the group with breast cancer (stage IV with progression of disease) in 85%. In all other groups (healthy controls, benign diseases of the breast, breast cancer before operation, breast cancer stage I (NED), breast cancer stage II and III (NED), and breast cancer stage IV (PR/CR), TPA was higher only in 5-22%. TPA determinations seem not to be very useful for diagnostic purposes in breast cancer, but it can be regarded as suitable for monitoring proliferative processes in advanced breast cancer. Limitations result from lack of tumor specificity of the proliferation marker TPA. So far, follow-up studies after mastectomy in breast cancer and in patients with advanced breast cancer under chemotherapy have shown that CEA and TPA are concordant. There is no cross reactivity between CEA and TPA. The main component of the labeled tracer has an isoelectric point of 4.4 but there is some impurity in the tracer as it was shown in chromatofocusing.

Breast Neoplasms↗
PubMedDate not supplied

Phase II evaluation of 5-fluourouracil plus folinic acid and alpha 2b-interferon in metastatic colorectal cancer.

Biochemical modulation of 5-fluorouracil (5-FU) by folinic acid (FA) increases the response rate in patients with metastatic colorectal cancer compared to 5-FU alone. Phase II trials also demonstrated increased efficacy when interferon was added to 5-FU. In two consecutive trials, 76 patients were treated on days 1-5 with FA 200 mg/m2 plus interferon 5 x 10(6) U/m2 and 5-FU 350 mg/m2 as intravenous bolus injection (n = 33, regimen A) or 5-FU 500 mg/m2 as 2-hour infusion (n = 43, regimen B), repeated every 3 weeks with individual 5-FU dose escalation in steps of 50 (regimen A) or 100 mg/m2 (regimen B). In regimen A 5-FU dose reduction to 300 mg/m2 due to toxicity was necessary in 49% of the patients; in regimen B a 5-FU dose of 600 mg/m2 or above was tolerated by 70% of the patients. Dose-limiting toxicity was severe mucositis and/or diarrhea. Objective responses were observed in 5 of 33 patients (15%) in regimen A (3-28%, 95% confidence interval) and 7 of 41 patients (17%) in regimen B (5-29%, 95% confidence interval). Median time to progression was 4.7 and 4.8 months, and median survival 9.9 and 11.4 months for regimens A and B, respectively. Prolonged 5-FU administration over 2 h allows the administration of a higher 5-FU dose compared to bolus injection with no apparent improvement in antineoplastic efficacy. The addition of interferon to the combination of 5-FU plus FA in this dose and schedule does not seem to improve the response rate but appears to increase treatment toxicity.

Adult↗
PubMedDate not supplied

Mastectomy stimulates prolactin release in breast cancer patients.

Hyperprolactinaemia has been described to occur after mastectomy in breast cancer patients, but whether it may be the result of surgery or breast cancer is particularly unknown. Plasma prolactin levels were measured in 51 patients one day before, and 1, 7, 30, and 180 days after mastectomy (23 primary breast cancer patients), tumourectomy (10 patients with benign or malignant breast lesions), and cholecystectomy (18 patients with cholelithiasis). Elevated prolactin levels were found on the 7th and 30th postoperative day in mastectomized and laparotomized patients, but not in patients who underwent tumourectomy of benign or malignant breast lesions (p less than 0.01). The prolactin levels were in the normal range one day before and again 180 days after surgery in all patients. We conclude, therefore, that postoperative hyperprolactinaemia in breast cancer patients is a result of surgery rather than the disease.

Adult↗
PubMedDate not supplied

Grading system for breast cancer.

As recurrence rates in breast cancer depend significantly on degree of malignancy (6-9) and mitotic rates as part of the grading system are difficult to assess in exact manner, we widened the grading system by evaluation of the proliferative compartment to get more information about proliferation activity as an important factor for tumor-progression (15, 16). This additional analysis can be used as a control factor for the correctness of the evaluation of mitotic activity. We practice this procedure at present as a "working formulation". New antibodies are in preparation which allow to exclude the highly variable G1-Phase. Further precision and control of degree of malignancy can be achieved by photometric analysis of S-Phase, 5c exceeding rate and state of ploidy according to Auer scheme.

Adult↗